After the closing of the stock market on the afternoon of April 13th, the company released the 2020 annual performance report (hereinafter referred to as the report) and the 2021 first quarter performance increase announcement (hereinafter referred to as the announcement). The report showed that the company's total operating revenue in 2020 was 758 million yuan, an increase of 11.29% year-on-year; The net profit attributable to shareholders of the listed company was 164 million yuan, a year-on-year increase of 24.45%, with a 27% increase after deducting non net profit; The basic earnings per share were 0.98 yuan, a year-on-year increase of 24.05%. Announcement disclosure: The company is expected to achieve a net profit of 44.8 million to 46.8 million yuan in the first quarter of this year, with a year-on-year increase of 82.90% to 91.10% in net profit. From the data disclosed in the performance report and pre increase announcement, it can be seen that the company has successfully completed various economic indicators and tasks planned for the 13th Five Year Plan period, and has successfully achieved a good start in the first quarter of the 14th Five Year Plan!
On March 22, 2021, the 11th meeting of the third board of directors of the company was held to discuss important matters.
The year 2020 has come to a perfect end. The success of the first quarter of 2021 was mainly attributed to two main factors: firstly, the company's main product - glucosamine hydrochloride capsules won the bid in the first place in the national drug centralized procurement in August 2020, obtaining the largest clinical market share of 41% in the country. The operating revenue of glucosamine hydrochloride capsules increased by about 60% year-on-year in the first quarter of this year, contributing to the thickening of the company's performance. Secondly, last year the company acquired 28.77% of the equity of Zhejiang Kangle Pharmaceutical Co., Ltd., obtaining an investment income of approximately 15 million yuan, resulting in an increase in net profit.
On March 18th, Vice General Manager Lv Zhidong (first from left) introduced the company's efforts to improve product quality to experts from Wenzhou Medical University Affiliated Ophthalmology Hospital who visited and inspected Workshop 106.
At the beginning of the year, the company was re evaluated and recognized as a "National High tech Enterprise", and Shanghai Ruicheng Biomedical Technology Co., Ltd. was established to work with Shanghai Ruijin Hospital to promote the industrialization of scientific research achievements in the "pancreatic duct built-in tube" and "cross shaped flushing drainage tube" as soon as possible. In early March, the company's newly built "Small Capacity Injection Workshop (i.e. Workshop 105)" passed the "GMP Compliance Inspection". The workshop has non final sterilization production lines and final sterilization production lines, and is rated as the "Zhejiang Digital Workshop". The company is currently researching 26 projects, including 6 consistency evaluation projects. A preparation method of narabine has been granted a national patent.
After winning the bid for ammonia sugar centralized procurement, the company successively held various forms of academic presentations and promotion meetings in key cities in China. The picture shows an academic promotion event held in Chengdu on November 2nd last year.
On March 11th, Dongwu Securities released a research report, giving the company a "buy" rating for the first time. The report stated that the company "has the advantage of integrating formulations and raw materials", is a "leading domestic marine biopharmaceutical manufacturing enterprise", and its leading product ammonia sugar has a "broad market space". It is expected to become an advantageous enterprise with revenue exceeding 1 billion yuan by 2025, providing more investment opportunities for investors.
Dongwu Securities released a research report, giving the company a "buy" rating for the first time.